Purinergic signalling in the lower urinary tract

Acta Physiologica

Volumn 207, Issue 1, 2013, Pages 40-52

  Burnstock, G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acupuncture; ATP; Bladder; Cancer; Prostate; Ureter

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR;

ACUPUNCTURE; BLADDER; BLADDER CANCER; BLADDER DISTENSION; CYSTALGIA; HUMAN; MEDICAL LITERATURE; MICTURITION REFLEX; NONHUMAN; PARASYMPATHETIC NERVE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSORY NERVE; SIGNAL TRANSDUCTION; URETHRA; UROGENITAL TRACT DISEASE; UROTHELIUM;

ANIMALS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, PURINERGIC; SIGNAL TRANSDUCTION; URETER; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84870810484     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12012     Document Type: Review

References (116)

1. Abraham, E.H., Salikhova, A.Y. & Rapaport, E. 2003. ATP in the treatment of advanced cancer. Curr Top Membr 54, 415-452.
2. Agteresch, H.J., Dagnelie, P.C., Rietveld, T., van den Berg, J.W., Danser, A.H. & Wilson, J.H. 2000a. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol 56, 49-55.
3. Agteresch, H.J., Dagnelie, P.C., van der Gaast, A., Stijnen, T. & Wilson, J.H. 2000b. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92, 321-328.
4. Andersson, K.E. & Hedlund, P. 2002. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 60, 13-20.
5. Artim, D.E., Birder, L.A. & de Groat, W.C. 2007. Purinergic mechanisms in human bladder cancer. FASEB J 21, 954.4.
6. Baqi, Y., Weyler, S., Iqbal, J., Zimmermann, H. & Müller, C.E. 2009. Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 5, 91-106.
7. Birder, L.A., Ruan, H.Z., Chopra, B., Xiang, Z., Barrick, S., Buffington, C.A., Roppolo, J.R., Ford, A.P., de Groat, W.C. & Burnstock, G. 2004. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am J Physiol Renal Physiol 287, F1084-F1091.
8. 3 receptor immunoreactive nerves in rat taste buds. NeuroReport 10, 1107-1111.
9. Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F.H., Delmas, P.D. & Clezardin, P. 1997. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57, 3890-3894.
10. Burnstock, G. 1972. Purinergic nerves. Pharmacol Rev 24, 509-581.
11. Burnstock, G. 1976. Do some nerve cells release more than one transmitter? Neuroscience 1, 239-248.
12. Burnstock, G. 1978. A basis for distinguishing two types of purinergic receptor. In: R.W. Straub & L. Bolis (eds) Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach, pp. 107-118. Raven Press, New York, NY.
13. Burnstock, G. 1999. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat 194, 335-342.
14. Burnstock, G. 2001a. Purinergic signalling in lower urinary tract. In: M.P. Abbracchio & M. Williams (eds) Handbook of Experimental Pharmacology, Volume 151/I. Purinergic and Pyrimidinergic Signalling I - Molecular, Nervous and Urinogenitary System Function, Chapt. 15, pp. 423-515. Springer-Verlag, Berlin.
15. Burnstock, G. 2001b. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 22, 182-188.
16. Burnstock, G. 2007a. Purine and pyrimidine receptors. Cell Mol Life Sci 64, 1471-1483.
17. Burnstock, G. 2007b. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87, 659-797.
18. Burnstock, G. 2009a. Purinergic mechanosensory transduction and visceral pain. Mol Pain 5, 69.
19. Burnstock, G. 2009b. Purinoceptors in the upper urinary tract. In: U. Simonsen, F. Andreasen & J. Mortensento (eds) Aspects of Pharmacology of the Pyeloureter with Clinical Perspectives, Chapt. 6, pp. 77-84. Research Signpost, Kerala, India.
20. Burnstock, G. 2009c. Acupuncture: a novel hypothesis for the involvement of purinergic signalling. Med Hypotheses 73, 470-472.
21. 2-purinoceptor? Gen Pharmacol 16, 433-440.
22. Burnstock, G. & Knight, G.E. 2004. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240, 31-304.
23. Burnstock, G. & Verkhratsky, A. 2009. Evolutionary origins of the purinergic signalling system. Acta Physiol 195, 415-447.
24. Burnstock, G. & Verkhratsky, A. 2010. Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis 1, e9.
25. Burnstock, G., Dumsday, B. & Smythe, A. 1972. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br J Pharmacol 44, 451-461.
26. Burnstock, G., Cocks, T., Crowe, R. & Kasakov, L. 1978. Purinergic innervation of the guinea-pig urinary bladder. Br J Pharmacol 63, 125-138.
27. 3 receptor expression on suburothelial sensory nerves. Purinergic Signalling 4, 377-381.
28. Chancellor, M.B., Fowler, C.J., Apostolidis, A., de Groat, W.C., Smith, C.P., Somogyi, G.T. & Aoki, K.R. 2008. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5, 319-328.
29. Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. & Wood, J.N. 1995. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377, 428-431.
30. Chen, L., He, H.Y., Li, H.M., Zheng, J., Heng, W.J., You, J.F. & Fang, W.G. 2004. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215, 239-247.
31. 2 receptor sensitizes mouse bladder sensory neurons and facilitates purinergic currents. J Neurosci 30, 2365-2372.
32. Cheng, Y., Mansfield, K.J., Allen, W., Walsh, C.A., Burcher, E. & Moore, K.H. 2010. Does adenosine triphosphate released into voided urodynamic fluid contribute to urgency signaling in women with bladder dysfunction? J Urol 183, 1082-1086.
33. 3-deficient mice. Nature 407, 1011-1015.
34. 2-purinoceptors on a human prostate cancer cell line (PC3 cells). Br J Pharmacol 114, 106P.
35. 7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151, 571-579.
36. Engberg, S., Cohen, S. & Sereika, S.M. 2009. The efficacy of acupuncture in treating urge and mixed incontinence in women: a pilot study. J Wound Ostomy Continence Nurs 36, 661-670.
37. 2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J Clin Investig 89, 191-196.
38. Feng, L., Sun, X., Csizmadia, E., Han, L., Bian, S., Murakami, T., Wang, X., Robson, S.C. & Wu, Y. 2011. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 13, 206-216.
39. Fernando, K.C., Gargett, C.E. & Wiley, J.S. 1999. Activation of the P2Z/P2X7 receptor in human lymphocytes produces a delayed permeability lesion: involvement of phospholipase D. Arch Biochem Biophys 362, 197-202.
40. Ford, A.P., Gever, J.R., Nunn, P.A., Zhong, Y., Cefalu, J.S., Dillon, M.P. & Cockayne, D.A. 2006. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 147(Suppl 2), S132-S143.
41. Gever, J., Cockayne, D.A., Dillon, M.P., Burnstock, G. & Ford, A.P.D.W. 2006. Pharmacology of P2X channels. Pflugers Arch 452, 513-537.
42. Gever, J.R., Rothschild, S., Henningsen, R., Martin, R., Hackos, D., Panicker, S., Rubas, W., Oglesby, I., Dillon, M.P., Milla, M.E., Burnstock, G. & Ford, A.P.D.W. 2010. AF-353, a novel, potent orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 160, 1387-1398.
43. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E. et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178.
44. Greig, A.V.H., Linge, C., Healy, V., Lim, P., Clayton, E., Rustin, M.H., McGrouther, D.A. & Burnstock, G. 2003. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Investig Dermatol 121, 315-327.
45. Harvey, R.A., Skennerton, D.E., Newgreen, D. & Fry, C.H. 2002. The contractile potency of adenosine triphosphate and ecto-adenosine triphosphatase activity in guinea pig detrusor and detrusor from patients with a stable, unstable or obstructed bladder. J Urol 168, 1235-1239.
46. 2+ flashes and contractility evoked by muscarinic receptor activation in mouse urinary bladder smooth muscle. J Physiol 587, 5275-5288.
47. 2X-purinoceptors and for purinergic transmission. Eur J Pharmacol 174, 115-118.
48. 2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol 377, 483-490.
49. 3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11, 1132-1145.
50. Janssens, R. & Boeynaems, J.M. 2001. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol 132, 536-546.
51. 2/3 receptors in the spinal cord. J Neurosci 30, 4503-4507.
52. 2-purinoceptor: effect on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. Eur J Pharmacol 86, 291-294.
53. Knight, G.E., Bodin, P., de Groat, W.C. & Burnstock, G. 2002. ATP is released from guinea pig ureter epithelium on distension. Am J Physiol Renal Physiol 282, F281-F288.
54. Koiso, K., Nemoto, R., Ohtani, M., Uchida, K., Shimazui, T., Noguchi, R., Hattori, K., Miyanaga, N., Shiraiwa, H. & Iwasaki, A. 1991. Evaluation of the invasive potential of superficial bladder cancer by adenosine triphosphate measurement. Urol Int 46, 145-148.
55. Korcok, J., Raimundo, L.N., Ke, H.Z., Sims, S.M. & Dixon, S.J. 2004. Extracellular nucleotides act through P2X7 receptors to activate NF-κB in osteoclasts. J Bone Miner Res 19, 642-651.
56. Kyprianou, N. & Isaacs, J.T. 1989. "Thymineless" death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun 165, 73-81.
57. Lawrence, G.W., Aoki, K.R. & Dolly, J.O. 2010. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther 334, 1080-1086.
58. Lee, Y.H., Lee, W.C., Chen, M.T., Huang, J.K., Chung, C. & Chang, L.S. 1992. Acupuncture in the treatment of renal colic. J Urol 147, 16-18.
59. 3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 377, 432-435.
60. Mackenzie, I., Burnstock, G. & Dolly, J.O. 1982. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7, 997-1006.
61. Martikainen, P., Kyprianou, N., Tucker, R.W. & Isaacs, J.T. 1991. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res 51, 4693-4700.
62. Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.L., Zitvogel, L. & Kroemer, G. 2009. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723-3728.
63. Martins, J.P., Silva, R.B., Coutinho-Silva, R., Takiya, C.M., Battastini, A.M., Morrone, F.B. & Campos, M.M. 2012. P2X7 purinergic receptor and its role in inflammatory and nociceptive alterations associated to cyclophosphamide-induced hemorrhagic cystitis in mice. Br J Pharmacol 165, 183-196.
64. McCarthy, C.J., Zabbarova, I.V., Brumovsky, P.R., Roppolo, J.R., Gebhart, G.F. & Kanai, A.J. 2009. Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity. J Urol 181, 1459-1466.
65. Minelli, A., Bellezza, I., Agostini, M., Bracarda, S. & Culig, Z. 2006. Mechanism of 2-chloroadenosine toxicity to PC3 cell line. Prostate 66, 1425-1436.
66. Minelli, A., Bellezza, I., Tucci, A., Rambotti, M.G., Conte, C. & Culig, Z. 2009. Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate 69, 538-547.
67. Miyake, H., Hara, I., Yamanaka, K., Arakawa, S. & Kamidono, S. 1999. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. J Urol 162, 916-921.
68. 2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem 284, 21257-21264.
69. Mönkkönen, H., Kuokkanen, J., Holen, I., Evans, A., Lefley, D.V., Jauhiainen, M., Auriola, S. & Mönkkönen, J. 2008. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19, 391-399.
70. 5 receptor innervation in human detrusor from adults with urge incontinence. J Neurosci 21, RC166:1-6.
71. Nandigama, R., Padmasekar, M., Wartenberg, M. & Sauer, H. 2006. Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells. J Biol Chem 281, 5686-5693.
72. Nergårdh, A. 1981. Neuromuscular transmission in the corpus-fundus of the urinary bladder. An in vitro study in the cat. Scand J Urol Nephrol 15, 103-108.
73. Nishiguchi, J., Sasaki, K., Seki, S., Chancellor, M.B., Erickson, K.A., de Groat, W.C., Kumon, H. & Yoshimura, N. 2004. Effects of isolectin B4-conjugated saporin, a targeting cytotoxin, on bladder overactivity induced by bladder irritation. Eur J Neurosci 20, 474-482.
74. Nucciarelli, F., Mearini, E. & Minelli, A. 2003. Effect of adenosine on prostate adenocarcinoma PC-3 and bladder carcinoma J82 cell lines. Drug Dev Res 58, 390-395.
75. O'Reilly, B.A., Kosaka, A.H., Chang, T.K., Ford, A.P., Popert, R. & McMahon, S.B. 2001. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int 87, 617-622.
76. O'Reilly, B.A., Kosaka, A.H., Knight, G.E., Chang, T.K., Ford, A.P.D.W., Rymer, J.M., Popert, R., Burnstock, G. & McMahon, S.B. 2002. P2X receptors and their role in female idiopathic detrusor instability. J Urol 167, 157-164.
77. Palea, S., Artibani, W., Ostardo, E., Trist, D.G. & Pietra, C. 1993. Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis. J Urol 150, 2007-2012.
78. Phelps, P.T., Anthes, J.C. & Correll, C.C. 2006. Characterization of adenosine receptors in the human bladder carcinoma T24 cell line. Eur J Pharmacol 536, 28-37.
79. Ralevic, V. & Burnstock, G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50, 413-492.
80. Rapaport, E. 1983. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol 114, 279-283.
81. Rocha, I., Burnstock, G. & Spyer, K.M. 2001. Effect on urinary bladder function and arterial blood pressure of the activation of putative purine receptors in brainstem areas. Auton Neurosci 88, 6-15.
82. Rong, W. & Burnstock, G. 2004. Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig. Neuropharmacology 47, 1093-1101.
83. Rong, W., Burnstock, G. & Spyer, K.M. 2000. P2X purinoceptor-mediated excitation of trigeminal lingual nerve terminals in an in vitro intra-arterially perfused rat tongue preparation. J Physiol 524, 891-902.
84. 5 receptor on satellite cells. J Cell Biol 158, 345-355.
85. 2+ response and growth stimulation of multicellular tumor spheroids are mediated by ATP release and purinergic receptor stimulation. J Cell Sci 115, 3265-3273.
86. Shabbir, M. & Burnstock, G. 2009. Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases. Int J Urol 16, 143-150.
87. Shabbir, M., Ryten, M., Thompson, C.S., Mikhailidis, D.P. & Burnstock, G. 2008a. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int 101, 106-112.
88. Shabbir, M., Thompson, C.S., Jarmulowicz, M., Mikhailidis, D.P. & Burnstock, G. 2008b. Effect of extracellular ATP on the growth of hormone refractory prostate cancer in vivo. BJU Int 102, 108-112.
89. Shabbir, M., Ryten, M., Thompson, C.S., Mikhailidis, D.P. & Burnstock, G. 2008c. Characterisation of calcium-independent purinergic receptor-mediated apoptosis in hormone refractory prostate cancer. BJU Int 101, 352-359.
90. Shemon, A.N., Sluyter, R., Fernando, S.L., Clarke, A.L., Dao-Ung, L.P., SkarRatt, K.K., Saunders, B.M., Tan, K.S., Gu, B.J., Fuller, S.J., Britton, W.J., Petrou, S. & Wiley, J.S. 2006. A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281, 2079-2086.
91. Sibley, G.N. 1984. A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J Physiol 354, 431-443.
92. 7 receptors. Histopathology 44, 206-215.
93. Smith, D.J. & Chapple, C.R. 1994. In vitro response of human bladder smooth muscle in unstable obstructed male bladders: a study of pathophysiological causes. Neurourol Urodyn 13, 414-415.
94. Smith, C.P., Vemulakonda, V.M., Kiss, S., Boone, T.B. & Somogyi, G.T. 2005. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 47, 291-297.
95. Stagg, J. & Smyth, M.J. 2010. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346-5358.
96. Stella, J., Bavaresco, L., Braganhol, E., Rockenbach, L., Farias, P.F., Wink, M.R., Azambuja, A.A., Barrios, C.H., Morrone, F.B. & Oliveira Battastini, A.M. 2010. Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol 28, 260-267.
97. Sugaya, K., Nishijima, S., Kadekawa, K., Miyazato, M. & Mukouyama, H. 2009. Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder. Biomed Res 30, 287-294.
98. 3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol 171, 448-452.
99. Sun, Y., Keay, S., Deyne, P. & Chai, T. 2001. Stretch-activated release of adenosine triphosphate by bladder uroepithelia is augmented in interstitial cystitis. Urology 57, 131.
100. Tapia-Vieyra, J.V. & Mas-Oliva, J. 2001. Apoptosis and cell death channels in prostate cancer. Arch Med Res 32, 175-185.
101. Tempest, H.V., Dixon, A.K., Turner, W.H., Elneil, S., Sellers, L.A. & Ferguson, D.R. 2004. P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU Int 93, 1344-1348.
102. Tjon Eng Soe, S.H., Kopsky, D.J., Jongen, P.J.H., de Vet, H.C.W. & Oei-Tan, C.L. 2009. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler 15, 1376-1377.
103. Tong, Y., Jia, Q., Sun, Y., Hou, Z. & Wang, Y. 2009. Acupuncture in the treatment of diabetic bladder dysfunction. J Altern Complement Med 15, 905-909.
104. Vanoverberghe, K., Mariot, P., Vanden, A.F., Delcourt, P., Parys, J.B. & Prevarskaya, N. 2003. Mechanisms of ATP-induced calcium signaling and growth arrest in human prostate cancer cells. Cell Calcium 34, 75-85.
105. 3 knockout mice reveal a major sensory role for urothelially released ATP. J Neurosci 21, 5670-5677.
106. Wang, Q., Li, X., Wang, L., Feng, Y.H., Zeng, R. & Gorodeski, G. 2004. Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 145, 5568-5579.
107. Wasilenko, W.J., Cooper, J., Palad, A.J., Somers, K.D., Blackmore, P.F., Rhim, J.S., Wright, G.L. Jr & Schellhammer, P.F. 1997. Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 30, 167-173.
108. 1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem Pharmacol 82, 418-425.
109. 11 receptor and cAMP pathways. Hypertension 36, 1093-1098.
110. White, N. & Burnstock, G. 2006. P2 receptors and cancer. Trends Pharmacol Sci 27, 211-217.
111. Yegutkin, G.G. 2008. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783, 673-694.
112. Yegutkin, G.G., Marttila-Ichihara, F., Karikoski, M., Niemela, J., Laurila, J.P., Elima, K., Jalkanen, S. & Salmi, M. 2011. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 41, 1231-1241.
113. Yoshida, M., Homma, Y., Inadome, A., Yono, M., Seshita, H., Miyamoto, Y., Murakami, S., Kawabe, K. & Ueda, S. 2001. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol 36, 99-109.
114. Young, J.S., Meng, E., Cunnane, T.C. & Brain, K.L. 2008. Spontaneous purinergic neurotransmission in the mouse urinary bladder. J Physiol 586, 5743-5755.
115. Yuping, W., Runfang, L. & Hua, K. 2006. Acupuncture treatment of children nocturnal enuresis - a report of 56 cases. J Tradit Chin Med 26, 106-107.
116. Zhang, Y., Gong, L.H., Zhang, H.Q., Du, Q., You, J.F., Tian, X.X. & Fang, W.G. 2010. Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. Cancer Lett 293, 189-197.